SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

다국어 초록 (Multilingual Abstract)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes. While the mechanisms underlying the salutary effects of SGLT2 inhibitors have not been fully elucidated, there is clear evidence for a beneficial metabolic effect of these drugs. In this review, we discuss the effects of SGLT2 inhibitors on cardiac energy provision secondary to ketone bodies, pathological ventricular remodeling, and inflammation in patients with HF. While the specific contribution of ketone bodies to the pleiotropic cardiovascular benefits of SGLT2 inhibitors requires further clarification, ketone bodies themselves may also be used as a therapy for HF.

참고문헌 (Reference)

1 Croteau E, "[11C]-Acetoacetate PET imaging : a potential early marker for cardiac heart failure" 41 : 863-870, 2014

2 Armstrong PW, "Vericiguat in patients with heart failure and reduced ejection fraction" 382 : 1883-1893, 2020

3 Misra S, "Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis" 32 : 14-23, 2015

4 Suzuki M, "Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models" 4 : e125-, 2014

5 Yurista SR, "Therapeutic potential of ketone bodies for patients with cardiovascular disease : JACC focus seminar" 77 : 1660-1669, 2021

6 Honka H, "Therapeutic manipulation of myocardial metabolism : JACC state-of-the-art review" 77 : 2022-2039, 2021

7 Briasoulis A, "The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure" 21 : 169-176, 2016

8 Adijanto J, "The retinal pigment epithelium utilizes fatty acids for ketogenesis" 289 : 20570-20582, 2014

9 Halestrap AP, "The monocarboxylate transporter family--structure and functional characterization" 64 : 1-9, 2012

10 Halestrap AP, "The monocarboxylate transporter family--role and regulation" 64 : 109-119, 2012

11 Butts B, "The importance of NLRP3 inflammasome in heart failure" 21 : 586-593, 2015

12 Neubauer S, "The failing heart--an engine out of fuel" 356 : 1140-1151, 2007

13 Horton JL, "The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense" 4 : e124079-, 2019

14 Aubert G, "The failing heart relies on ketone bodies as a fuel" 133 : 698-705, 2016

15 Lan NSR, "The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function : current evidence and future directions" 6 : 927-935, 2019

16 Johnson RH, "The effect of exercise upon acetoacetate metabolism in athletes and non-athletes" 57 : 73-79, 1972

17 Cherney DZ, "The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus" 13 : 28-, 2014

18 Volek JS, "The art and science of low carbohydrate performance: a revolutionary program to extend your physical and mental performance envelope" Beyond Obesity LLC 2012

19 Chasis H, "The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man" 12 : 1083-1090, 1933

20 Iannantuoni F, "The SGLT2inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes" 8 : 1814-, 2019

21 Swanson KV, "The NLRP3 inflammasome : molecular activation and regulation to therapeutics" 19 : 477-489, 2019

22 Tsao CW, "Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction" 6 : 678-685, 2018

23 Deng Y, "Targeting mitochondria-inflammation circuit by β-hydroxybutyrate mitigates HFpEF" 128 : 232-245, 2021

24 Jones NR, "Survival of patients with chronic heart failure in the community : a systematic review and meta-analysis" 21 : 1306-1325, 2019

25 Shimazu T, "Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor" 339 : 211-214, 2013

26 Kong Y, "Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy" 113 : 2579-2588, 2006

27 Dhillon KK, "StatPearls" StatPearls 2021

28 Bhatt DL, "Sotagliflozin in patients with diabetes and recent worsening heart failure" 384 : 117-128, 2021

29 Yurista SR, "Sodiumglucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction" 21 : 862-873, 2019

30 Yabe D, "Sodium-glucose cotransporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes : a randomized, open-label, 3-arm parallel comparative, exploratory study" 19 : 739-743, 2017

31 Ekanayake P, "Sodium-glucose cotransporter type 2(SGLT-2)inhibitors and ketogenesis : the good and the bad" 20 : 74-, 2020

32 Kashiwagi A, "Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients" 12 : 6-20, 2021

33 Di Franco A, "Sodium-dependent glucose transporters(SGLT)in human ischemic heart : a new potential pharmacological target" 243 : 86-90, 2017

34 Ferrannini E, "Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes" 65 : 1190-1195, 2016

35 Stryeck S, "Serum concentrations of citrate, tyrosine, 2-and 3-hydroxybutyrate are associated with increased 3-month mortality in acute heart failure patients" 9 : 6743-, 2019

36 Inagaki N, "Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus : post hoc subgroup analyses according to body mass index in a 52-week open-label study" 16 : 1577-1591, 2015

37 Yokono M, "SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats" 727 : 66-74, 2014

38 Taylor SI, "SGLT2 inhibitors may predispose to ketoacidosis" 100 : 2849-2852, 2015

39 Cowie MR, "SGLT2 inhibitors : mechanisms of cardiovascular benefit beyond glycaemic control" 17 : 761-772, 2020

40 Kim SR, "SGLT2 inhibition modulates NLRP3inflammasome activity via ketones and insulin in diabetes with cardiovascular disease" 11 : 2127-, 2020

41 Sattar N, "SGLT2 Inhibition and cardiovascular events : why did EMPA-REG Outcomes surprise and what were the likely mechanisms?" 59 : 1333-1339, 2016

42 Bourg CA, "Rosiglitazone, myocardial ischemic risk, and recent regulatory actions" 46 : 282-289, 2012

43 Home PD, "Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis" 357 : 28-38, 2007

44 Kim GH, "Reverse remodelling and myocardial recovery in heart failure" 15 : 83-96, 2018

45 Cohen JJ, "Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin" 184 : 91-96, 1956

46 McGarry JD, "Regulation of hepatic fatty acid oxidation and ketone body production" 49 : 395-420, 1980

47 Santos-Gallego CG, "Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction" 77 : 243-255, 2021

48 Kramer DG, "Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction : a meta-analytic approach" 56 : 392-406, 2010

49 Robinson AM, "Physiological roles of ketone bodies as substrates and signals in mammalian tissues" 60 : 143-187, 1980

50 Miao Z, "Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin(PF-04971729)in healthy male subjects" 41 : 445-456, 2013

51 Scheen AJ, "Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose cotransporter 2 inhibitor" 53 : 213-225, 2014

52 Burchfield JS, "Pathological ventricular remodeling : mechanisms : part 1 of 2" 128 : 388-400, 2013

53 Tran MT, "PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection" 531 : 528-532, 2016

54 Cotter DG, "Obligate role for ketone body oxidation in neonatal metabolic homeostasis" 286 : 6902-6910, 2011

55 Sengenes C, "Natriuretic peptides: a new lipolytic pathway in human fat cells" 21 : 29-33, 2005

56 Duewell P, "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals" 464 : 1357-1361, 2010

57 Grebe A, "NLRP3 inflammasome and the IL-1 pathway in atherosclerosis" 122 : 1722-1740, 2018

58 Karwi QG, "Myocardial ketones metabolism in heart failure" 26 : 998-1005, 2020

59 Lopaschuk GD, "Myocardial fatty acid metabolism in health and disease" 90 : 207-258, 2010

60 Puchalska P, "Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics" 25 : 262-284, 2017

61 Hegardt FG, "Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase : a control enzyme in ketogenesis" 338 : 569-582, 1999

62 Grubić Rotkvić P, "Minireview : are SGLT2 inhibitors heart savers in diabetes?" 25 : 899-905, 2020

63 Ferrannini E, "Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients" 124 : 499-508, 2014

64 Bertero E, "Metabolic remodelling in heart failure" 15 : 457-470, 2018

65 Mitchell GA, "Medical aspects of ketone body metabolism" 18 : 193-216, 1995

66 Requena-Ibáñez JA, "Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF : from the EMPA-TROPISM study" 9 : 578-589, 2021

67 Lopaschuk GD, "Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2(SGLT2)inhibitors : a state-of-the-art review" 5 : 632-644, 2020

68 Zelniker TA, "Mechanisms of Cardiorenal effects of sodium-glucose cotransporter 2inhibitors : JACC state-of-the-art review" 75 : 422-434, 2020

69 Birkenfeld AL, "Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans" 90 : 3622-3628, 2005

70 Konstam MA, "Left ventricular remodeling in heart failure : current concepts in clinical significance and assessment" 4 : 98-108, 2011

71 Qiu H, "Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors : basic mechanisms and therapeutic perspectives" 33 : e2886-, 2017

72 Ho KL, "Ketones can become the major fuel source for the heart but do not increase cardiac efficiency" 117 : 1178-1187, 2021

73 Lopaschuk GD, "Ketone metabolism in the failing heart" 1865 : 158813-, 2020

74 Yurista SR, "Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure" 14 : e007684-, 2021

75 Balasse EO, "Ketone body production and disposal : effects of fasting, diabetes, and exercise" 5 : 247-270, 1989

76 Cotter DG, "Ketone body metabolism and cardiovascular disease" 304 : H1060-H1076, 2013

77 Gormsen LC, "Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans : a positron emission tomography study" 6 : 6-, 2017

78 Yurista SR, "Ketone bodies for the failing heart : fuels that can fix the engine?" 32 : 814-826, 2021

79 Laffel L, "Ketone bodies : a review of physiology, pathophysiology and application of monitoring to diabetes" 15 : 412-426, 1999

80 Ingwall JS, "Is the failing heart energy starved? On using chemical energy to support cardiac function" 95 : 135-145, 2004

81 Sengenes C, "Involvement of a cGMPdependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes" 278 : 48617-48626, 2003

82 Polidori D, "Intra-and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose cotransporter 2 inhibitor canagliflozin" 20 : 1321-1326, 2018

83 Sato K, "Insulin, ketone bodies, and mitochondrial energy transduction" 9 : 651-658, 1995

84 Mehta JL, "Inflammation in heart failure : the holy grail?" 68 : 27-29, 2016

85 Ho KL, "Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency" 115 : 1606-1616, 2019

86 Voros G, "Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling" 11 : e004953-, 2018

87 Selvaraj S, "Implications of altered ketone metabolism and therapeutic ketosis in heart failure" 141 : 1800-1812, 2020

88 Keller U, "Human ketone body production and utilization studied using tracer techniques : regulation by free fatty acids, insulin, catecholamines, and thyroid hormones" 5 : 285-298, 1989

89 McGarry JD, "Hormonal control of ketogenesis. Biochemical considerations" 137 : 495-501, 1977

90 Ye Y, "High-energy phosphate metabolism and creatine kinase in failing hearts : a new porcine model" 103 : 1570-1576, 2001

91 Huynh K, "Heart failure : ketone bodies as fuel in heart failure" 13 : 122-123, 2016

92 Braunwald E, "Heart failure" 1 : 1-20, 2013

93 Virani SS, "Heart disease and stroke statistics-2021 update : a report from the American Heart Association" 143 : e254-e743, 2021

94 Virani SS, "Heart disease and stroke statistics-2020 update : a report from the American Heart Association" 141 : e139-e596, 2020

95 Benjamin EJ, "Heart disease and stroke statistics-2018 update : a report from the American Heart Association" 137 : e67-e492, 2018

96 Xie M, "HDAC-dependent ventricular remodeling" 23 : 229-235, 2013

97 Cahill GF Jr, "Fuel metabolism in starvation" 26 : 1-22, 2006

98 Straw S, "Four pillars of heart failure : contemporary pharmacological therapy for heart failure with reduced ejection fraction" 8 : e001585-, 2021

99 Yokokawa T, "Exhaled acetone concentration is related to hemodynamic severity in patients with non-ischemic chronic heart failure" 80 : 1178-1186, 2016

100 Bedi KC Jr, "Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure" 133 : 706-716, 2016

101 Brooke J, "Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis : a systematic review" 13 : 837-, 2016

102 Groenewegen A, "Epidemiology of heart failure" 22 : 1342-1356, 2020

103 Lopaschuk GD, "Empagliflozin’s fuel hypothesis : not so soon" 24 : 200-202, 2016

104 Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes" 373 : 2117-2128, 2015

105 Grempler R, "Empagliflozin, a novel selective sodium glucose cotransporter-2(SGLT-2)inhibitor : characterisation and comparison with other SGLT-2 inhibitors" 14 : 83-90, 2012

106 Tikkanen I, "Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension" 38 : 420-428, 2015

107 Verma S, "Empagliflozin increases cardiac energy production in diabetes : novel translational insights into the heart failure benefits of SGLT2 inhibitors" 3 : 575-587, 2018

108 Anker SD, "Empagliflozin in heart failure with a preserved ejection fraction" 385 : 1451-1461, 2021

109 Moellmann J, "Empagliflozin improves left ventricular diastolic function of db/db mice" 1866 : 165807-, 2020

110 Connelly KA, "Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction" 4 : 27-37, 2019

111 Santos-Gallego CG, "Empagliflozin Ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics" 73 : 1931-1944, 2019

112 Yokokawa T, "Elevated exhaled acetone concentration in stage C heart failure patients with diabetes mellitus" 17 : 280-, 2017

113 Cohen ND, "Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes : a cardiac magnetic resonance study" 49 : 1006-1010, 2019

114 Mullens W, "Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring" 7 : 2071-2073, 2020

115 Oldgren J, "Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes : A randomized, placebo-controlled, exploratory study" 23 : 1505-1517, 2021

116 Verma S, "Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes : an important clue to the EMPA-REG OUTCOME trial?" 39 : e212-e213, 2016

117 Pietschner R, "Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure" 20 : 219-, 2021

118 Lu Y, "Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients : a meta-analysis of randomized controlled trials" 87 : 20-28, 2021

119 McMurray JJ, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure : rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial(PARADIGM-HF)" 15 : 1062-1073, 2013

120 WildenhoffKE, "Diurnal variations in the concentrations of blood acetoacetate and 3-hydroxybutyrate. The ketone body peak around midnight and its relationship to free fatty acids, glycerol, insulin, growth hormone and glucose in serum and plasma" 195 : 25-28, 1974

121 Meng W, "Discovery of dapagliflozin : a potent, selective renal sodium-dependent glucose cotransporter 2(SGLT2)inhibitor for the treatment of type 2 diabetes" 51 : 1145-1149, 2008

122 Al Jobori H, "Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients" 19 : 809-813, 2017

123 McMurray JJV, "Dapagliflozin in patients with heart failure and reduced ejection fraction" 381 : 1995-2008, 2019

124 Merovci A, "Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production" 124 : 509-514, 2014

125 Daniele G, "Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes" 39 : 2036-2041, 2016

126 Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes" 380 : 347-357, 2019

127 McDonagh TA, "Corrigendum to : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)With the special contribution of the Heart Failure Association(HFA)of the ESC" 42 : 4901-, 2021

128 Murashige D, "Comprehensive quantification of fuel use by the failing and nonfailing human heart" 370 : 364-368, 2020

129 Kashiwagi Y, "Close linkage between blood total ketone body levels and B-type natriuretic peptide levels in patients with cardiovascular disorders" 11 : 6498-, 2021

130 Dick SA, "Chronic heart failure and inflammation : what do we really know?" 119 : 159-176, 2016

131 Puisac B, "Characterization of splice variants of the genes encoding human mitochondrial HMG-CoA lyase and HMG-CoA synthase, the main enzymes of the ketogenesis pathway" 39 : 4777-4785, 2012

132 Yokokawa T, "Change of exhaled acetone concentration levels in patients with acute decompensated heart failure" 59 : 808-812, 2018

133 Staels B, "Cardiovascular protection by sodium glucose cotransporter 2 inhibitors : potential mechanisms" 130 : S30-S39, 2017

134 Nielsen R, "Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients" 139 : 2129-2141, 2019

135 Packer M, "Cardiovascular and renal outcomes with empagliflozin in heart failure" 383 : 1413-1424, 2020

136 Schugar RC, "Cardiomyocytespecific deficiency of ketone body metabolism promotes accelerated pathological remodeling" 3 : 754-769, 2014

137 Uchihashi M, "Cardiac-specific Bdh1overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure" 10 : e004417-, 2017

138 Cohn JN, "Cardiac remodeling--concepts and clinical implications : a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling" 35 : 569-582, 2000

139 Teerlink JR, "Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure" 384 : 105-116, 2021

140 Abdul Kadir A, "Cardiac ketone body metabolism" 1866 : 165739-, 2020

141 Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes" 377 : 644-657, 2017

142 Mudaliar S, "Can a Shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis" 39 : 1115-1122, 2016

143 Ferrannini E, "CV protection in the EMPA-REG OUTCOME trial : a"Thrifty Substrate"hypothesis" 39 : 1108-1114, 2016

144 Klocker AA, "Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in type 1 diabetes : a systematic review" 30 : 818-824, 2013

145 Chu Y, "Beta-hydroxybutyrate, friend or foe for stressed hearts" 2 : 681513-, 2021

146 Birkenfeld AL, "Atrial natriuretic peptide induces postprandial lipid oxidation in humans" 57 : 3199-3204, 2008

147 Davis MA, "Association between apple consumption and physician visits : appealing the conventional wisdom that an apple a day keeps the doctor away" 175 : 777-783, 2015

148 White JR Jr, "Apple trees to sodium glucose co-transporter inhibitors : a review of SGLT2 inhibition" 28 : 5-10, 2010

149 Petersen C, "Analyse des phloridzins" 15 : 178-, 1835

150 Guerci B, "Advantages to using capillary blood beta-hydroxybutyrate determination for the detection and treatment of diabetic ketosis" 31 : 401-406, 2005

151 Weiss RG, "ATP flux through creatine kinase in the normal, stressed, and failing human heart" 102 : 808-813, 2005

152 McMurray JJV, "A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction(DAPA-HF)" 21 : 665-675, 2019

153 Hugo SE, "A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting" 26 : 282-293, 2012

154 Muhammad Akram, "A Focused Review of the Role of Ketone Bodies in Health and Disease" 한국식품영양과학회 16 (16): 965-967, 2013

155 Writing Committee, "2021 update to the 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment : answers to 10 pivotal issues about heart failure with reduced ejection fraction : a report of the American College of Cardiology Solution Set Oversight Committee" 77 : 772-810, 2021

156 Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC" 37 : 2129-2200, 2016

157 Du Z, "1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients" 9 : e88102-, 2014